Since most renal cell carcinoma patients are accompanied by VHL gene mutations, which lead to activation of the HIF pathway and hypoxia, anti-angiogenic drugs are mainly used to directly or indirectly block the downstream signaling pathways of VEGF and its receptors in the treatment of renal cell carcinoma to achieve intervention. Here, VEGFA is linked to renal cell carcinoma.